✦ LIBER ✦

A phase I study of AIT-082 in healthy elderly volunteers

✍ Scribed by Michael Grundman; Martin Farlow; Guerry Peavy; Hyun T. Kim; Edmund Capparelli; Arlan N. Schultz; David P. Salmon; Steven H. Ferris; Richard Mohs; Ronald G. Thomas; Kimberly Schafer; Karen Campbell; Ann Marie Hake; Barbara Schoos; Leon J. Thal; the Alzheimer’s Disease Cooperative Study

Book ID: 111639618
Publisher: Humana Press Inc
Year: 2002
Tongue: English
Weight: 158 KB
Volume: 18
Category: Article
ISSN: 0895-8696
DOI: 10.1385/jmn:18:3:283

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of monohydroxyethylrutos

A phase I study of monohydroxyethylrutoside in healthy volunteers

✍ Anja M. Willems; Anne M. Bruynzeel; Marc A. Kedde; Cees J. van Groeningen; Aalt 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 311 KB

Safety evaluation of BacoMind™ in health

Safety evaluation of BacoMind™ in healthy volunteers: A phase I study

✍ K. Pravina; K.R. Ravindra; K.S. Goudar; D.R. Vinod; A.J. Joshua; P. Wasim; K. Ve 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 580 KB

Selection of healthy volunteers for phas

Selection of healthy volunteers for phase I studies

✍ M. Sibille 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB

Phase I Clinical Study of Edaravone in H

Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers

✍ Hao Li, Kun Xu, Dr. Yongqing Wang, Hongwen Zhang, Tianping Li, Ling Meng… 📂 Article 📅 2012 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 142 KB

Adverse events in phase-I studies: a rep

Adverse events in phase-I studies: a report in 1015 healthy volunteers

✍ M. Sibille; N. Deigat; A. Janin; S. Kirkesseli; D. Vital Durand 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 280 KB

Adverse events in phase one studies: a s

Adverse events in phase one studies: a study in 430 healthy volunteers

✍ M. Sibille; N. Deigat; V. Olagnier; D. Vital Durand; R. Levrat 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 445 KB

All the clinical, laboratory and electrocardiographic adverse events detected during 24 Phase I studies in the same unit over a 5 y period are reported here. 430 healthy male volunteers were involved, corresponding to 5488 days of follow-up. The overall incidence of adverse events was 13.5%, with a